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Abstract: The Organization for Economic Cooperation and Development (OECD) tracks and 
reports on more than 1,200 health system measures across 34 industrialized countries. This 
analysis concentrated on 2010 OECD health data for Australia, Canada, Denmark, France, 
Germany, Netherlands, New Zealand, Norway, Sweden, Switzerland, the United Kingdom, 
and the United States. Health care spending in the U.S. towers over the other countries. The 
U.S. has fewer hospital beds and physicians, and sees fewer hospital and physician visits, than 
in most other countries. Prescription drug utilization, prices, and spending all appear to be 
highest in the U.S., as does the supply, utilization, and price of diagnostic imaging. U.S. per-
formance on a limited set of quality measures is variable, ranking highly on five-year cancer 
survival, middling on in-hospital case-specific mortality, and poorly on hospital admissions for 
chronic conditions and amputations due to diabetes. Findings suggest opportunities for cross-
national learning to improve health system performance.
                    
OVERVIEW
Findings from cross-national comparisons of health care systems can inform pub-
lic policy, highlight areas where nations could improve, and yield benchmarks for 
high performance. The Organization for Economic Cooperation and Development 
(OECD) annually tracks and reports on more than 1,200 health system measures 
across 34 industrialized countries, ranging from population health status and non-
medical determinants of health to health care resources and utilization. Since 1998, 
The Commonwealth Fund has sponsored an analysis of cross-national health systems 
based on OECD health data to place the performance of the U.S. health system in 
an international context.
This analysis examined 2010 OECD health data for 12 countries (Australia, 
Canada, Denmark, France, Germany, Netherlands, New Zealand, Norway, Sweden, 
Switzerland, the United Kingdom, and the United States) as well as data from 
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the 2009 OECD Health Care Quality Indicators—an 
OECD project initiated in 2002 that aims to measure 
and compare the quality of health service provision across 
countries. Data on drug utilization and prices, as well as 
magnetic resonance imaging (MRI) prices, from other 
sources were also included. 
Among the 12 countries, the U.S. differs mark-
edly on a number of health system measures.1 Health 
care spending in the U.S. in 2008 towered over the 
comparison countries, both per capita and as a percent-
age of gross domestic product (GDP). The U.S. had a 
comparatively low number of hospital beds and physi-
cians per capita, and patients in the U.S. had fewer hos-
pital and physician visits than in most other countries. 
However, hospital spending per visit was highest in the 
U.S. Prescription drug utilization, prices, and spending 
all appeared highest in the U.S., as did the supply, utili-
zation, and price of diagnostic imaging. With regard to 
quality, U.S. performance on a limited set of measures 
was variable. Five-year survival rates for patients with 
three types of cancer were relatively high; the U.S. ranked 
near the middle on in-hospital, case-specific mortality for 
three conditions within 30 days of admission. The U.S. 
also had among the highest rates of hospital admissions 
for five chronic conditions and the greatest number of 
lower-extremity amputations due to diabetes. These find-
ings suggest that the U.S. health system is not delivering 
superior results despite being more expensive, indicat-
ing opportunities for cross-national learning to improve 
health system performance.
KEY FINDINGS
The comparative findings from the OECD that follow 
are for 2008, although data for 2007 and 2006 were used 
in some instances, as indicated in the exhibits. Where 
data from those years were not available, no data are 
presented. The median for all OECD countries is also 
included in Exhibits 1, 4, and 5; for Exhibits 6, 8, 9, 
10, and 11, the median is included for only the coun-
tries shown, due to incompleteness of data. All currency 
amounts are listed in U.S. dollars (USD) and adjusted for 
national differences in cost of living.
The United States Continues to Outspend All Other 
Countries on Health Care (Exhibits 1, 2, and 3) 
•	 In 2008, health care spending in the U.S. reached 
$7,538 per capita—far more than in any other 
country studied and more than double the OECD 
median of $2,995. Health care spending in the 
next-highest spending countries—Norway and 
Switzerland—was less than two-thirds as much per 
capita ($5,003 and $4,627, respectively). In all but 
two of the remaining eight countries, spending per 
capita was less than half the U.S. figure, and in New 
Zealand it was close to one-third ($2,683).
•	 The U.S. spent 16 percent of its GDP on health 
care. This proportion was nearly double the OECD 
median (8.7%) and over 40 percent more than the 
country spending the second-largest share of GDP 
(France 11.2%). 
•	 From 1998 to 2008, health care spending per capita 
in the U.S. grew at an annual adjusted rate of 3.4 
percent. This rate was slightly below the OECD 
median (3.9%). Health care spending in several 
countries, like Norway (0.8%), rose markedly slower, 
while in others, like the U.K. (4.9%), spending rose 
markedly faster. Health care spending growth in the 
U.S. since 1980 has dwarfed that of the other coun-
tries, both per capita and as a percentage of GDP 
(Exhibit 2).
•	 Breaking down the distribution of health care financ-
ing in 2008 by source, the U.S. stood out with far 
greater private health care spending excluding out-of-
pocket payments ($3,119) than the other countries, 
which rely on government-payer or social insurance 
models rather than private insurance.2 Out-of-pocket 
spending was also higher in the U.S. ($912) than in 
all other countries except Switzerland ($1,424), likely 
reflecting cost-sharing and coverage gaps.3 Yet even 
with more than half of total health care spending 
coming from private sources, per capita public health 
care spending in the U.S. ($3,507), primarily in 
Medicare and Medicaid, outstripped public spending 
in all other countries, except for Norway ($4,213) 
(Exhibit 3). 
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Exhibit 1. Health Spending in Select OECD Countries, 2008
Total Health Spending
Per capitac Percent GDP
Average annual real growth rate per capita: 
1998–2008
Australia $3,353a 8.5%a 3.6%a
Canada $4,079e 10.4%e 3.4%e
Denmark $3,540a 9.7%a 3.5%a
France $3,696 11.2% 2.3%
Germany $3,737 10.5% 1.8%
Netherlands $4,063e 9.9%e 4.1%e
New Zealand $2,683 9.9% 4.4%
Norway $5,003e 8.5%e 0.8%e
Sweden $3,470 9.4% 3.9%
Switzerland $4,627e 10.7%e 1.9%e
United Kingdom $3,129 8.7% 4.9%
United States $7,538 16.0% 3.4%
OECD median $2,995 8.7% 3.9%
a 2007. 
c Adjusted for differences in cost of living. 
e Estimate. 
Source: OECD Health Data 2010 (Oct. 2010).
Note: PPP = purchasing power parity—an estimate of the exchange rate required to equalize the purchasing power of different currencies, given the prices 
of goods and services in the countries concerned.
Source: OECD Health Data 2010 (Oct. 2010).
Exhibit 2. International Comparison of Spending on Health, 1980–2008
Average spending on health
per capita ($US PPP)
Total expenditures on health
as percent of GDP
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Relatively Few Physicians and Physician Visits in the 
United States (Exhibit 4)
•	 In 2008, the U.S. had the fewest practicing physi-
cians per 1,000 population (2.43) among the 10 
countries where data were available, and was below 
the OECD median (3.00).
•	 There were four doctor consultations per capita in 
the U.S., which was tied with Switzerland for the sec-
ond-fewest among the 12 countries, and well below 
the OECD median (6.4 per capita). Only Sweden 
had fewer consultations (2.9); Germany had nealry 
twice as many (7.8). 
Hospital Admission Rates Lower and Stays Shorter in 
the U.S., but Higher Spending per Discharge (Exhibits 
4 and 5)
•	 In 2008, the supply of acute-care hospital beds in 
the U.S. (2.7 per 1,000 population) was below the 
OECD median (3.3 per 1,000 population). Only 
New Zealand (2.2) and Norway (2.7) had fewer beds 
per 1,000, while Germany stood out with the most 
beds (5.7 per 1,000 population). 
•	 The average length of stay for acute care in the U.S. 
was 5.5 days, which was shorter than six countries 
and the OECD median, but longer than Sweden 
(4.5 days), Norway (4.8 days), and France (5.2 
days). Since 1980, average length of stay has notably 
decreased in all countries where data is available, 
including the U.S. which has historically had among 
the shortest stays (data not shown).
•	 Most countries had more hospital discharges than the 
U.S. (130 per 1,000 population), which was below 
the OECD median (161 per 1,000 population).
•	 Although hospital stays were relatively infrequent and 
short in the U.S., hospital spending per discharge 
far exceeded all other countries at $16,708—nearly 
triple the OECD median of $5,949. The country 
with the second-highest spending, Canada, spent 
only 75 percent as much per discharge ($12,669), 
and in both Germany and France, hospital stays were 
*2007.
Source: OECD Health Data 2010 (Oct. 2010).
Exhibit 3. Health Care Expenditure per Capita by Source of Funding, 2008
Adjusted for Differences in Cost of Living
Dollars
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Exhibit 4. Supply and Utilization of Doctors and Hospitals in Select OECD Countries, 2008
Physician Supply and Use Hospital Supply, Use, and Spending
Practicing 
physicians per 
1,000 pop.
Doctor 
consultations  
per capita
Acute care 
hospital beds  
per 1,000 pop.
Average length of 
stay for acute care 
(days)
Hospital 
discharges  
per 1,000 pop.
Australia 2.97a 6.4 3.5b 5.9b 163a
Canada —f 5.7a 2.7a 7.5a 84a
Denmark 3.42a 8.9 3.0 —f 159
France —f 6.9 3.5 5.2 264
Germany 3.56 7.8 5.7 7.6 232
Netherlands —f 5.9 2.9 5.9 113
New Zealand 2.46 4.3a 2.2 —f 140
Norway 4.01 —f 2.5 4.8 172
Sweden 3.58b 2.9 —f 4.5a 165a
Switzerland 3.82 4.0a 3.3 7.7 169
United Kingdom 2.61 5.9 2.7 7.1 136
United States 2.43 4.0a 2.7a 5.5 130b
OECD median 3.00 6.4 3.3 6.0 161
a 2007. 
b 2006. 
f Data not available. 
Source: OECD Health Data 2010 (Oct. 2010).
* 2007.
 ** 2006.
Source: OECD Health Data 2010 (Oct. 2010).
Exhibit 5. Hospital Spending per Discharge, 2008
Adjusted for Differences in Cost of Living
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nearly one-quarter as expensive ($4,566 and $4,762, 
respectively) (Exhibit 5). 
The U.S. Has the Highest Drug Utilization, Prices, 
and Spending (Exhibits 6 and 7)
•	 According to The Commonwealth Fund 2010 
International Health Policy Survey in 11 Countries, 
adults in the U.S. were the most likely to take at 
least one prescription drug regularly (61%) and 
to take at least four prescription drugs regularly 
(25%).4 Switzerland had the lowest drug utilization. 
Compared with the U.S., only two-thirds as many 
Swiss adults were taking a regular prescription (40%) 
and only two-fifths were taking at least four prescrip-
tions (10%). 
•	 An analysis by Gerard Anderson of data from IMS 
Health found that 2006–07 prices for the 30 most-
commonly prescribed drugs were highest in the U.S., 
with drugs in Canada second-most expensive (0.77 
relative to 1.00 price level in the U.S.).5 Of the seven 
other countries for which data were available, four 
had price levels that were less than half the U.S. level 
(Exhibit 7).6
•	 Not surprising, given the higher rates of utilization 
and higher prices, spending in 2008 on pharmaceu-
ticals was highest in the U.S. among the 12 coun-
tries, at $897 per capita (data not shown). A 2008 
analysis of OECD data conducted by consulting 
firm McKinsey found that the U.S. annually spends 
$98 billion more on pharmaceuticals than would be 
expected based on per-capita income relative to other 
wealthy countries, and that this higher spending is 
due both to higher prices and a more expensive drug 
mix.7 
•	 Pharmaceutical spending per capita in the U.S. also 
increased at the highest average annual real growth 
Exhibit 6. Supply, Use, and Price of Pharmaceuticals in Select OECD Countries 
Pharmaceutical Use, 2010g Pharmaceutical Spending
% adults taking at 
least one prescription 
regularly
% adults taking 
at least four 
prescriptions regularly
Per capita, 
2008c
% total health 
spending, 
2008
Average 
annual real 
growth rate 
per capita: 
1998–2008
Australia 54% 18% $480a 14.3%a 4.9%a
Canada 56% 17% $701e 17.2%e 4.6%e
Denmark —f —f $303a 8.6%a 2.9%a
France 45% 17% $607 16.4% 3.0%
Germany 54% 12% $563 15.1% 2.9%
Netherlands 56% 15% —f —f —f
New Zealand 55% 18% $257 9.6% 0.8%a
Norway 54% 14% $381e 7.6%e –0.8%e
Sweden 50% 17% $457 13.2% 3.5%
Switzerland 40% 10% $461a 10.3%a 2.0%a
United Kingdom 52% 13% $368 11.8% 2.3%a
United States 61% 25% $897 11.9% 5.3%
Median (countries shown) 54% 17% $461 11.9% 3.5%
a 2007. 
c Adjusted for differences in cost of living. 
e Estimate. 
f Data not available. 
g Source: Commonwealth Fund 2010 International Health Policy Survey of Eleven Countries. 
Source: OECD Health Data 2010 (Oct. 2010), unless otherwise specified.
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rate of 5.3 percent between 1998 and 2008, com-
pared with growth of less than 1 percent in New 
Zealand (0.8%) and negative growth in Norway 
(–0.8%) (data not shown). 
•	 Despite having the highest per capita spending on 
pharmaceuticals as a percentage of total health care 
spending, the U.S. (11.9%) ranked near the middle 
of the other countries included in the analysis, 
reflecting the higher cost of the U.S. system as a 
whole (data not shown). 
Wide Proliferation of Diagnostic Imaging at  
High Prices (Exhibit 8)
•	 The U.S. had a large supply of diagnostic imaging 
machines in 2008 compared with the other countries 
for which data were available. Computerized tomog-
raphy (CT) scanners were prevalent in the U.S. (34.3 
per million population) compared with other coun-
tries, with only Australia (56.0 per million popula-
tion) having more. The U.S. also had the most MRI 
machines (25.9 per million population) of any of the 
six countries where data was available. 
•	 Use of diagnostic imaging in 2008 was highest 
in the U.S., with more CT and MRI exams per-
formed—228 and 91 per 100,000 population, 
respectively—than in any of the six countries where 
data was available.
•	 According to an analysis by the International 
Federation of Health Plans, MRI scan and imag-
ing fees in 2009 were highest in the U.S. ($1,200) 
among the six countries for which data was 
available.8
The U.S. Sees More Hospital Admissions for Chronic 
Conditions (Exhibit 9)
•	 Of five chronic conditions, the U.S. had the highest 
hospital admissions rates for three in 2007: asthma 
(120 per 100,000 population), congestive heart 
failure (441 per 100,000 population), and diabetes 
acute complications (57 per 100,000 population). 
The U.S. had the fifth-highest rate of admissions 
for chronic obstructive pulmonary disease among 
11 countries (203 per 100,000 population), and 
the sixth-highest rate of admission for hypertension 
among 10 countries (49 per 100,000 population).
Source: IMS Health.
Exhibit 7. Drug Prices for 30 Most Commonly Prescribed Drugs, 2006–07
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•	 Lower-extremity amputations due to diabetes were 
performed at a rate of 36 per 100,000 population 
among adults age 15 and older in the U.S— the 
highest rate among these countries. 
Variable Rates of Five-Year Cancer Survival and 
Cancer Mortality in the U.S. (Exhibit 10)
•	 From 2002 to 2007, the five-year survival rate for 
three cancers in the U.S. was relatively high among 
the eight countries reporting though the ranking 
varied by condition. For breast cancer, the five-year 
survival rate in the U.S. was 90.5 percent, the high-
est among the eight countries reporting and 12 
percentage points higher than the lowest performer 
(the U.K. at 78.5%). The five-year survival rate 
for colorectal cancer was also highest in the U.S. at 
65.5%, which was nearly 14 percentage points higher 
than the lowest performer (the U.K. at 51.6%). On 
cervical cancer, the U.S. (67.0%) ranked fourth out 
of eight countries reporting, behind New Zealand 
(67.7%), the Netherlands (69.0%), and Canada 
(71.9%). 
•	 The U.S. had middling-to-low rates of mortality 
due to cervical cancer (2.1 per 100,000 population), 
breast cancer (20.7 per 100,000 population), and 
colorectal cancer (14.4 per 100,000 population). Of 
the nine countries for which data were available, only 
the U.S. and France had mortality rates below the 
median for all three types of cancer.
Variable Rates of In-Hospital Case-Fatality in the U.S. 
(Exhibit 11)
•	 Rates of in-hospital case-fatality—that is, the ratio 
of in-hospital deaths among people admitted with a 
particular condition—within 30 days of admission 
for three conditions was available for eight countries. 
For acute myocardial infarction, the U.S. had the 
Exhibit 8. Supply, Use, and Price of Diagnostic Imaging in Select OECD Countries 
MRI Machines CT Scanners
Devices per 
million pop., 
2008
Exams per 
100,000 pop., 
2008
MRI scan and 
imaging fees, 
2009g
Devices per 
million pop., 
2008
Exams per 
100,000 pop., 
2008
Australia 5.6 21d —f 56.0b,e 94d
Canada 6.7a 42 $824 12.7a 122
Denmark —f 38 —f 21.5 84
France —f 49 $436 —f 130
Germany —f —f $839 —f —f
Netherlands 10.4 39 $567 10.3 60
New Zealand 9.6 —f —f 12.4 —f
Switzerland —f —f —f 32.0 —f
United Kingdom 6.9 —f $179 10.2 —f
United States 25.9a 91a $1,200 34.3a 228a
Median (countries shown) 8.3 40 $696 17.1 108
Note: Data on CT scanners and MRI units do not include those outside hospitals in Germany and only for a small number in France. For the United Kingdom, the data refer only 
to scanners in the public sector. For Australia, the number of MRI units includes only those eligible for reimbursement under Medicare, the universal public health system; in 1999, 
60% of total MRI units were eligible for Medicare reimbursement. Also for Australia and France, data for CT and MRI exams refer only to utilization by out-patients and private 
in-patients (excluding those in public hospitals). Data not available for Norway or Sweden. 
a 2007. 
b 2006. 
d Difference in methodology. 
e Estimate. 
f Data not available. 
g Source: International Federation of Health Plans, 2009 Comparative Price Report. 
Source: OECD Health Data 2010 (Oct. 2010), unless otherwise specified.
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third-highest fatality rate (5.1 per 100 patients), and 
for hemorrhagic stroke, the second-highest fatality 
rate (25.5 per 100 patients). For ischemic stroke, the 
U.S. had the fourth-lowest fatality rate (4.2 per 100 
patients). Denmark (acute myocardial infarction: 2.9 
per 100 patients; hemorrhagic stroke: 16.7 per 100 
patients; ischemic stroke: 3.1 per 100 patients) and 
Sweden (acute myocardial infarction: 2.9 per 100 
patients; hemorrhagic stroke: 12.8 per 100 patients; 
ischemic stroke: 3.9 per 100 patients) had the lowest 
fatality rates for all three conditions.
WHAT IS DRIVING HIGHER HEALTH CARE 
SPENDING IN THE U.S.? 
Spending on health care in the U.S. in 2008 far exceeded 
that seen in other countries. In both dollar figures and as 
a percentage of GDP, no country came within 70 percent 
of U.S. spending ($7,538 per capita, 16% GDP). This 
higher spending does not seem to simply reflect higher 
income. In Norway, the only country studied with higher 
per capita income than the U.S., health care spending 
accounted for only 8.5% of GDP. 
Although much higher health care spending marks 
the U.S. as an outlier, containing spending growth is a 
shared challenge among these 12 countries. From 1998 
to 2008, all countries experienced a rate of growth that 
exceeded inflation, with growth expected to continue. 
A recent analysis from the Centers for Medicare and 
Exhibit 9. Hospital Admissions for Chronic Diseases and Diabetes Amputations in  
Select OECD Countries, 2007 
Hospital Admissions for Chronic Diseases  
per 100,000 Population, 
Age 15 and Older
Diabetes lower 
extremity 
amputations 
per 100,000 
population, age 
15 and olderAsthma
Chronic 
obstructive 
pulmonary 
disease
Congestive 
heart failure Hypertension
Diabetes  
acute 
 complications
Canada 18 190 146 15 23 11
Denmark 43 320 165 85 20 21
France 43 79 276 —e —e 13
Germany 21 184 352 213 14 —e
Netherlands 26b 154b 171b,d 19b 8b 11b
New Zealand 73 308 206 16 1 12
Norway 42 243 188 70 20 11
Sweden 25 192 289 61 19 12
Switzerland 32a 100a 155a 55a 12a 16a
United Kingdom 76 236 117 11 32 9
United States 120a,c 203a,c 441a,c 49a,c 57a,c 36a,c
Median (countries shown) 42 192 188 52 19.5 12
Age-sex standardized rates. Data not available for Australia. 
a 2006. 
b 2005. 
c U.S. does not fully exclude day cases. 
d Netherlands includes admissions for additional diagnosis codes, which marginally elevates rates. 
e Data not available. 
Source: OECD Health Care Quality Indicators Data 2009.
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Exhibit 10. Five-Year Survival and Mortality Rates for Cervical, Breast,  
and Colorectal Cancer in Select OECD Countries 
Cancer Five-Year Relative Survival Rate 
(%), 2002–07
Cancer Mortality Rates per 100,000 Pop., 
2007
Cervical cancer 
(females only)
Breast cancer 
(females only)
Colorectal 
cancer
Cervical cancer 
(females only)
Breast cancer 
(females only)
Colon 
cancer
Canada 71.9e 87.1 60.7e —g —g —g
Denmark 61.3 82.4 54.4 2.6a 28.6a 25.3a
France —g —g 57.1f 1.5 22.0 16.0
Netherlands 69.0d 85.2 58.1d 2.0a 24.0a 24.1a
New Zealand 67.7 82.1 60.9 1.7 25.3 20.8
Norway 65.9d 81.9 57.8d 2.7 17.9 21.8
Sweden 65.8c 86.1 59.8c 2.3 18.3 16.9
United Kingdom 59.4 78.5 51.6 2.2 24.4 17.1
United States 67.0e 90.5 65.5e 2.1b 20.7b 14.4b
Median (countries shown) 66.5 83.8 58.1 2.2 23.0 19.0
Age standardized rates (%). No data available for Australia, Germany, or Switzerland. 
a 2006. 
b 2005. 
c 2003–08. 
d 2001–06. 
e 2000–05. 
f 1997–02. 
g Data not available. 
Source: OECD Health Data 2010 (Oct. 2010) and OECD Health Care Quality Indicators Data 2009.
Exhibit 11. Rates of In-Hospital Case-Fatality Within 30 Days of Admission in Select OECD Countries 
In-Hospital Case-Fatality Within 30 Days of Admission per 100 Patients, 2007
Acute myocardial infarction Hemorrhagic stroke Ischemic stroke
Canada 4.2 23.2 7.6
Denmark 2.9 16.7 3.1
Netherlands 6.6b 25.2b 5.6b
New Zealand 3.3 23.8 6.3
Norway 3.2 13.7 3.3
Sweden 2.9 12.8 3.9
United Kingdom 6.3 26.3 9.0
United States 5.1a 25.5a 4.2a
Median (countries shown) 3.8 23.5 4.9
Note: Figures do not account for death that occurs outside of the hospital, possibly influencing the ranking for countries, such as the U.S., that have shorter 
lengths of stay.  Medicare data is available on 30-day mortality in the U.S., but this is not currently available from private insurers. 
Age-sex standardized rates (%). No data available for Australia, France, Germany, or Switzerland. 
a 2006. 
b 2005. 
Source: OECD Health Care Quality Indicators Data 2009.
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Medicaid Services projects U.S. national health expendi-
ture to grow at a rate of 6.1 percent from 2009 to 2019.9 
There are many forces driving health care spend-
ing. An annual series of Commonwealth Fund-sponsored 
analyses of OECD health data dating back to 1999 has 
explored a number of potential factors, including: admin-
istrative complexity, the aging of the population, the 
practice of “defensive medicine” under threat of malprac-
tice litigation, chronic disease burden, health care supply 
and utilization rates, access to care, resource allocation, 
and the use of technologically advanced equipment and 
procedures.10 These and other studies have found, con-
trary to often-cited explanations, the U.S. has a relatively 
young population, average or below-average rates of 
chronic conditions, and comparatively few doctor visits 
and hospitalizations compared with other industrialized 
countries.11 Instead, these studies suggest major reasons 
for higher spending include substantially higher prices 
and more fragmented care delivery that leads to duplica-
tion of resources and extensive use of poorly coordinated 
specialists.
Because of their uniformity, pharmaceuticals allow 
for a relatively direct comparison across countries. This 
analysis finds the U.S. to be highest among 12 countries 
on drug utilization, prices, and spending. In strong con-
trast, New Zealand stands out with the lowest per capita 
spending on pharmaceuticals—only 29 percent of what 
the U.S. spends—with almost no real growth in this fig-
ure over the past 10 years. The difference does not seem 
to stem from lower utilization. New Zealand adults on 
average consume the second-most prescriptions among 
the 12 countries, although they may take a less expen-
sive mix of drugs. Rather, the spending divergence likely 
appears to be largely because of pricing. The 30 most-
commonly prescribed drugs were three times cheaper in 
New Zealand than in the U.S. New Zealand’s success 
suggests possible policy lessons for the U.S., including 
nationally negotiated rates, reference pricing, and com-
parative cost-effectiveness review for new medications. 
These policies are already widely employed among other 
countries.12 
Despite much higher spending, U.S. performance 
in terms of quality is variable relative to other countries. 
While cancer care in the U.S. seems to be of particularly 
high quality based on five-year survival rates, the high 
rates of hospital admissions for chronic diseases sug-
gest opportunities for improvement. These results echo 
previous comparative studies that find the U.S. to have 
middling or highly uneven quality. A 2010 cross-national 
study conducted by The Commonwealth Fund ranked 
the U.S. sixth of seven countries in terms of quality, with 
average performance on effectiveness and patient-cen-
teredness and low performance on safety and coordina-
tion.13 With chronic disease on the rise amidst an aging 
demographic and accounting for ever more health care 
spending, more effective treatment and management in 
primary care settings may have the potential to simulta-
neously improve patient care while preventing the unnec-
essary use of scarce and expensive resources.14
12 The Commonwealth Fund
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